Celgene buys Delinia for $300mm plus earn-outs
Celgene Corp. is paying $300mm up front to acquire one-year-old private biotech Delinia Inc. The agreement also includes an additional $475mm in potential earn-out payments.
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.